Pregabalin, a specific ligand of the alpha-2-delta type 1 and 2 subunits of voltage-gated calcium ion channels, is used in the treatment of various types of intractable neuropathic pain (NP) such as postherpetic neuralgia (PHN) ([@b1-prm-19-e164]--[@b9-prm-19-e164]), diabetic peripheral neuropathy (DPNP) ([@b5-prm-19-e164]--[@b13-prm-19-e164]) and cancer-related NP ([@b14-prm-19-e164]). However, pregabalin administration is occasionally abandoned due to adverse events. The most commonly reported adverse events data (all-causality) with pregabalin (regardless of dose) in Japan were dizziness (PHN 31.1%; DPNP 24.6%), somnolence (PHN 28.6%; DPNP 25.7%), peripheral edema (PHN 12.5%; DPNP 15.1%) and weight gain (PHN 11.7%; DPNP 13.4%) ([@b15-prm-19-e164]). However, the exact causes of these differences in adverse events of pregabalin have not been elucidated. Therefore, the aim of the present study was to identify predictive factors for adverse events of pregabalin, which will help to establish evidence-based guidelines for the optimal use of pregabalin.

METHODS
=======

Study term and participants
---------------------------

The present study was a retrospective analysis involving 208 patients with NP who had been treated with pregabalin in the pain clinic at the University Hospital at Kyoto Prefectural University of Medicine (Kyoto, Japan) between July 2010 and September 2011. The study protocol was approved by the ethics review boards of Kyoto Prefectural University of Medicine.

Statistical analysis
--------------------

Multivariate logistic regression analysis was used to examine the relationships among various predictive factors and adverse events associated with pregabalin administered for the relief of NP. Analyzed adverse events were somnolence, unsteadiness, weight gain and edema. The occurrence of adverse events was recorded by pain clinicians based on interviews with the patients in daily clinical practice. The occurrence of an adverse event of grade ≥1 according to the Common Terminology Criteria for Adverse Events version 4.0 was regarded as a positive event. Variables were extracted from the clinical records for regression analysis of factors related to the occurrence of adverse events associated with pregabalin administration. Predictive variables included sex, age, body mass index, dose and duration of pregabalin therapy, laboratory tests, concomitant medications, combination therapies and target disease. Target diseases were PHN, cancer-related NP, failed back surgery syndrome, trigeminal neuralgia, complex regional pain syndrome, spine disease (spinal canal stenosis, osteoarthritis, hernia), DPNP and others. Concomitant drug use was defined as the administration of another drug for ≥2 weeks at the time of evaluation for adverse events. Body mass index and laboratory tests were extracted at the time of last evaluation. Binary scales were used for sex (female = 0; male = 1); age (\<60 years = 0; ≥60 years = 1); serum creatinine level (\<1.0 mg/dL \[88.4 μmol/L\] = 0; ≥1.0 mg/dL \[88.4 μmol/L\] = 1); initial dose (\<100 mg/day = 0; ≥100 mg/day = 1); maintenance dose (\<150 mg/day = 0; ≥150 mg/day = 1); and other variables (no = 0; yes = 1). Ordinal scales were ≤2 weeks = 0; \>2 weeks but ≤1 month = 1; \>1 month but ≤2 months = 2; and \>2 months = 3 for duration of therapy. All potential predictive variables were screened for multicollinearity, which was defined as a correlation coefficient \>0.7 between any two predictors. A lack of multicollinearity ensured the appropriate use of the multivariate regression model. Variables were further screened with the forward selection procedure, after which multivariate logistic regression analysis was performed using the selected variables. Threshold measures were examined using an ROC curve ([@b16-prm-19-e164]). All statistical analyses were performed using JMP version 9 (SAS Institute, USA) at a two-sided significance level of P\<0.05.

RESULTS
=======

Adverse events were observed in 118 patients (56.7%). Pregabalin was discontinued due to adverse events in 32 patients (15.4%). These adverse events comprised somnolence in nine patients, dizziness in two, unsteadiness in 16, weight gain in two and edema in four (some patients experienced two or three adverse events). All patients showed full resolution of symptoms after discontinuation of pregabalin. [Table 1](#t1-prm-19-e164){ref-type="table"} summarizes the clinical characteristics of the patients administered pregabalin, as well as the selected predictors related to adverse events of pregabalin. Predictive factors for adverse events were identified using logistic regression analysis. Predictive factors were: duration of therapy (OR 1.684 \[95% CI 1.179 to 2.406\]; P=0.0042) for somnolence; nonsteroidal anti-inflammatory drugs (NSAIDs) (OR 0.132 \[95% CI 0.030 to 0.578\]; P=0.0072), age (OR 3.137 \[95% CI 1.220 to 8.066\]; P=0.0177) and maintenance dose (OR 0.437 \[95% CI 0.217 to 0.880\]; P=0.0205) for unsteadiness; serum creatinine level (OR 6.439 \[95% CI 1.541 to 26.902\]; P=0.0107) for weight gain; and neurotropin (OR 8.538 \[95% CI 1.159 to 62.901\]; P=0.0353) and serum creatinine (OR 6.912 \[95% CI 1.118 to 42.726\]; P=0.0375) for edema. Accuracy refers to the ratio of patients whose expected value is equal to the observed value ([Table 2](#t2-prm-19-e164){ref-type="table"}). Using an ROC curve with a creatinine threshold \>0.83, the highest sensitivity (67%) and specificity (73%) were obtained for the occurrence of weight gain (area under the curve = 0.68); with a creatinine threshold \>1.02, the highest sensitivity (63%) and specificity (91%) were obtained for the occurrence of edema (area under the curve = 0.78).

DISCUSSION
==========

Our findings indicate that predictive factors for the occurrence of adverse events were: duration of therapy for somnolence; use of NSAIDs, age and maintenance dose for unsteadiness; serum creatinine for weight gain; and use of neurotropin and serum creatinine for edema.

Duration of therapy was identified as a predictive factor for somnolence. This result showed that pregabalin does not induce any tolerance for somnolence. The only predictor Frame et al ([@b17-prm-19-e164]) identified for the time to first nonzero dizziness or drowsiness score due to pregabalin was the daily titrated dose. Thus, clinicians need to consider reducing the dose of pregabalin if patients report feeling very sleepy. Tricyclic antidepressants (TCAs) showed a low, but not significant, OR for somnolence; this finding may suggest the safety of the combined use of pregabalin and TCAs. The combination of pregabalin and TCAs may be associated with reduced somnolence.

No administration of NSAIDs and advanced age were identified as significant factors for unsteadiness. Unsteadiness occurred even with relatively low maintenance doses. These findings suggest the safety of the combined use of pregabalin and NSAIDs. Clinicians need to exercise caution when administering pregabalin to elderly patients, due to the risk of unsteadiness. Addition of NSAIDs to the regimen of an elderly patient on pregabalin may mitigate the risk of unsteadiness. On the other hand, NSAIDs are independently associated with significant adverse effects, particularly in elderly patients (eg, unheralded gastrointestinal bleeding); clinicians should, therefore, be alert to combined use of pregabalin and NSAIDs in elderly patients. The safety of the combination of the agents would require more detailed study. In addition, pregabalin shows a linear pharmacokinetic profile ([@b18-prm-19-e164]). However, unsteadiness did not occur in a dose-dependent manner. Clinicians should, therefore, be alert to initial unsteadiness when prescribing pregabalin.

Elevated serum creatinine level was identified as a predictive factor for weight gain. Pregabalin is eliminated primarily unchanged by renal excretion ([@b19-prm-19-e164]); therefore, accumulation of pregabalin due to delayed elimination through the kidney may cause weight gain. Stephen et al ([@b20-prm-19-e164]) identified dose-related weight gain due to pregabalin; our results support that finding. Clinicians should be cautious when prescribing pregabalin to patients with altered renal function.

Elevated serum creatinine level and combination use with neurotropin were identified as predictive factors for edema. Cumulative dosage of pregabalin due to delayed elimination through the kidneys may cause edema in addition to weight gain, reinforcing the need for clinicians to exercise care regarding renal function when prescribing pregabalin. Neurotropin, a nonprotein extract isolated from inflamed rabbit skin after inoculation with vaccinia virus, acts on the descending pain inhibitory system and has been widely used in Japan for the treatment of disorders associated with chronic pain ([@b21-prm-19-e164]--[@b23-prm-19-e164]). Edema due to neurotropin has been reported infrequently; thus, the possibility of edema arising in combination use of pregabalin and neurotropin needs to be considered.

In our study, dizziness was observed in 2.9% of patients. On the other hand, previous studies have concluded that dizziness in patients treated with pregabalin occurred in 17% to 46% ([@b24-prm-19-e164],[@b25-prm-19-e164]). It may also be due to the difference in drug metabolism between Japanese and Caucasian patients, the difference in disease, or the low maintenance dose in the present study because the daily dose of our subjects was 152.2±96.4 mg whereas the dose used in previous studies was 300 mg to 600 mg ([@b24-prm-19-e164],[@b25-prm-19-e164]).

The present study had several limitations. First, the retrospective nature of the investigation may have decreased the reliability of the data collected. Second, the present study was performed at a single centre and involved a relatively small number of patients; therefore, the results should be confirmed in a further multicentre study.

CONCLUSION
==========

We used a statistical approach to identify factors predicting adverse events associated with administration of pregabalin for NP. Our findings indicate that care is warranted regarding long duration of therapy for somnolence, advanced age rather than dose-dependent adverse events for unsteadiness, elevated serum creatinine level for weight gain, and elevated serum creatinine level and combination use of neurotropin for edema. Our study also demonstrated the safety of the combined use of pregabalin and NSAIDs. These findings should be considered preliminary and in need of further refinement and study. However, statistical identification of predictive factors should contribute to establish optimal protocols for pregabalin use.
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###### 

Patient characteristics and extracted factors that may affect effectiveness or adverse effects associated with pregabalin for neuropathic pain (n=208)

  **Characteristic**                               **n (%)^[\*](#tfn1-prm-19-e164){ref-type="table-fn"}^**   **Mean ± SD (range)**
  ------------------------------------------------ --------------------------------------------------------- ----------------------------
  Adverse events                                   118 (56.7)                                                
    Somnolence                                     62 (29.8)                                                 
    Dizziness                                      6 (2.9)                                                   
    Unsteadiness                                   49 (23.6)                                                 
    Weight gain, kg, mean ± SD (median)            11 (5.3)                                                  4.45±1.98 (4.0) (2.6--9.0)
    Edema                                          9 (4.3)                                                   
  Demographic factors                                                                                        
    Male sex                                       88 (42.3)                                                 
    Age, ≥60 years                                 145 (69.7)                                                63.3±15.4 (19--91)
  Physical examination finding                                                                               
    Body mass index                                                                                          22.4±3.5 (15.2--34.5)
  Dose and duration of pregabalin therapy                                                                    
    Initial dose, mg/day, mean ± SD (median)       149 (71.6)                                                112.9±48.8 (100) (25--375)
    Maintenance dose, mg/day, mean ± SD (median)   111 (53.4)                                                152.2±96.4 (150) (25--450)
    Duration of therapy (0/1/2/3)                  34/25/31/118                                              
  Laboratory tests                                                                                           
    AST, U/L                                                                                                 24.3±13.6 (9--111)
    ALT, U/L                                                                                                 20.4±20.3 (4--236)
    Blood urea nitrogen                                                                                      
      mmol/L                                                                                                 5.7±2.1 (2.0--17.7)
      mg/dL                                                                                                  16.0±6.0 (5.6--49.5)
    Albumin, g/L                                                                                             40.8±5.1 (16--51)
    Bilirubin                                                                                                
      μmol/L                                                                                                 12.8±12.0 (3.9--157.1)
      mg/dL                                                                                                  0.75±0.70 (0.23--9.19)
    Serum creatinine                                                                                         
      μmol/L                                       22 (10.6)                                                 66.3±27.4 (30.1--231.6)
      mg/dL                                                                                                  0.75±0.31 (0.34--2.62)
  Concomitant medications                                                                                    
    Opioids                                        27 (13.0)                                                 
      Morphine                                     2                                                         
      Oxycodone                                    9                                                         
      Fentanyl                                     7                                                         
      Tramadol                                     1                                                         
      Others                                       8                                                         
    NSAIDS                                         43 (20.7)                                                 
    Neurotropin                                    12 (5.8)                                                  
    Benzodiazepine                                 44 (21.2)                                                 
    Tricyclic antidepressant                       22 (10.6)                                                 
  Combination therapies                                                                                      
    Nerve block                                    62 (29.8)                                                 
    Epiduroscopy                                   24 (11.5)                                                 
    Phototherapy                                   40 (19.2)                                                 
  Target diseases                                                                                            
    Postherpetic neuralgia                         75 (36.1)                                                 
    Cancer-related neuropathic pain                18 (8.7)                                                  
    Failed back surgery syndrome                   14 (6.7)                                                  
    Trigeminal neuralgia                           12 (5.8)                                                  
    Complex regional pain syndrome                 8 (3.8)                                                   
    Spine disease                                  21 (10.1)                                                 
      Spinal canal stenosis                        11 (5.3)                                                  
      Osteoarthritis                               7 (3.4)                                                   
      Hernia                                       3 (1.4)                                                   
    Diabetic peripheral neuropathy                 3 (1.4)                                                   
    Others                                         57 (27.4)                                                 

Binary scales were: female = 0 and male = 1 for sex; \<60 years of age = 0 and ≥60 years of age = 1 for age; \<1.0 mg/dL (88.4 μmol/L) = 0 and ≥1.0 mg/dL (88.4 μmol/L) = 1 for serum creatinine level; \<100 mg/day = 0 and ≥100 mg/day = 1 for initial dose; \<150 mg/day = 0 and ≥150 mg/day = 1 for maintenance dose; and absent = 0 and present = 1 for others. Ordinal scales were: ≤2 weeks = 0; \>2 weeks but ≤1 month = 1; \>1 month but ≤2 months = 2; and \>2 months = 3 for duration of therapy. ALT Alanine aminotransferase; AST Aspartate aminotransferase; NSAIDS Nonsteroidal anti-inflammatory drugs

###### 

Results of logistic regression analysis for variables extracted by forward selection

  **Variable**                                             **Estimated value**   **SE**   **χ^2^**   **P**                                                  **OR**   **95% CI**
  -------------------------------------------------------- --------------------- -------- ---------- ------------------------------------------------------ -------- ---------------
  **Response Y = somnolence (accuracy = 125/208)**                                                                                                                   
  Duration of therapy                                      0.521                 0.182    8.21       0.0042^[\*](#tfn2-prm-19-e164){ref-type="table-fn"}^   1.684    1.179--2.406
  TCA                                                      −0.811                0.669    1.47       0.2259                                                 0.445    0.120--1.651
  Opioid                                                   0.662                 0.513    1.67       0.1968                                                 1.938    0.710--5.295
  Serum creatinine                                         0.782                 0.581    1.81       0.1781                                                 2.186    0.700--6.826
  **Response Y = unsteadiness (accuracy = 159/208)**                                                                                                                 
  NSAIDs                                                   −2.027                0.755    7.21       0.0072^[\*](#tfn2-prm-19-e164){ref-type="table-fn"}^   0.132    0.030--0.578
  Age                                                      1.143                 0.482    5.63       0.0177^[\*](#tfn2-prm-19-e164){ref-type="table-fn"}^   3.137    1.220--8.066
  Maintenance dose                                         −0.828                0.357    5.37       0.0205^[\*](#tfn2-prm-19-e164){ref-type="table-fn"}^   0.437    0.217--0.880
  **Response Y = body weight gain (accuracy = 164/208)**                                                                                                             
  Neurotropin                                              1.473                 0.914    2.6        0.1068                                                 4.364    0.728--26.156
  Serum creatinine                                         1.862                 0.730    6.52       0.0107^[\*](#tfn2-prm-19-e164){ref-type="table-fn"}^   6.439    1.541--26.902
  **Response Y = edema (accuracy = 164/208)**                                                                                                                        
  Neurotropin                                              2.144                 1.019    4.43       0.0353^[\*](#tfn2-prm-19-e164){ref-type="table-fn"}^   8.538    1.159--62.901
  BUN                                                      0.0958                0.053    3.28       0.0701                                                 1.101    0.992--1.221
  Serum creatinine                                         1.933                 0.929    4.33       0.0375^[\*](#tfn2-prm-19-e164){ref-type="table-fn"}^   6.912    1.118--42.726

P\<0.05. BUN Blood urea nitrogen; NSAIDs Nonsteroidal anti-inflammatory drugs; TCA Tricyclic antidepressant
